Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy.
Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.